Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment

To identify liquid biomarkers that predict clinical outcomes of epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), we enrolled patients with EGFR gene mutation‐positive non–small‐cell lung cancer who were intended to receive gefitinib treatment. Using plasma samples obtained prio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ochiai, Ryosuke, Hayashi, Kentaro, Yamamoto, Hiroshi, Fujii, Risa, Saichi, Naomi, Shinchi, Hiroki, Ishida, Tsuyoshi, Honda, Takeshi, Shimizu, Tetsuo, Matsutani, Noriyuki, Seki, Nobuhiko, Kawamura, Masafumi, Ueda, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633313/
https://www.ncbi.nlm.nih.gov/pubmed/36028467
http://dx.doi.org/10.1111/cas.15512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633313/
https://www.ncbi.nlm.nih.gov/pubmed/36028467
http://dx.doi.org/10.1111/cas.15512

Ejemplares similares